Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up

Citation
S. Sironi et al., Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up, AM J ROENTG, 173(5), 1999, pp. 1225-1229
Citations number
21
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
Journal title
AMERICAN JOURNAL OF ROENTGENOLOGY
ISSN journal
0361803X → ACNP
Volume
173
Issue
5
Year of publication
1999
Pages
1225 - 1229
Database
ISI
SICI code
0361-803X(199911)173:5<1225:SHCTWP>2.0.ZU;2-I
Abstract
OBJECTIVE, The purpose of our study was to determine the usefulness of MR i maging in the follow-up evaluation of small hepatocellular carcinoma lesion s treated with RF ablation. SUBJECTS AND METHODS. The study group included 37 patients with a single he patocellular carcinoma lesion less than 3 cm in diameter. A strict protocol required followup MR imaging every 6 months after RF treatment. At each fo llow-up visit, the findings on unenhanced and dynamic gadolinium-enhanced M R images were correlated with those on contrast-enhanced CT images and with results of fine-needle aspiration biopsy. In five patients who underwent s urgical resection after the 6-month follow-up examination, comparison with histologic findings of surgical specimens was also performed. RESULTS. Correct diagnosis of complete or partial tumor necrosis was made i n 32 (86%) of the 37 patients with the use of unenhanced and dynamic gadoli nium-enhanced MR images. Hypointensity on T2-weighted images and loss of en hancement on dynamic MR images corresponded to completely necrotic lesions in all patients. Conversely, intratumoral regions of hyperintensity on T2-w eighted images and enhancement on dynamic MR images did not always correlat e to residual viable tumor. MR imaging and CT findings agreed in the evalua tion of therapeutic response in all patients. CONCLUSION. Our experience confirms that MR imaging is useful for evaluatin g the effectiveness of RF therapy in achieving tumor regression.